Benchmark on Drug Target Interaction Modeling from a Drug Structure Perspective

TMLR Paper4012 Authors

19 Jan 2025 (modified: 31 Mar 2025)Rejected by TMLREveryoneRevisionsBibTeXCC BY 4.0
Abstract: The prediction modeling of drug-target interactions is crucial to drug discovery and design, which has seen rapid advancements owing to deep learning technologies. Recently developed methods, such as those based on graph neural networks (GNNs) and Transformers, demonstrate exceptional performance across various datasets by effectively extracting structural information. However, the benchmarking of these novel methods often varies significantly in terms of hyperparameter settings and datasets, which limits algorithmic progress. In view of these, we conducted a comprehensive survey and benchmark for drug-target interaction modeling from a structure perspective, via integrating tens of explicit (i.e., GNN-based) and implicit (i.e., Transformer-based) structure learning algorithms. To this end, we first unify the hyperparameter setting within each class of structure learning methods. Moreover, we conducted a macroscopical comparison between these two classes of encoding strategies as well as the different featurization techniques that inform molecules' chemical and physical properties. We then carry out the microscopical comparison between all the integrated models across the six datasets, via comprehensively benchmarking their effectiveness and efficiency. Remarkably, the summarized insights from the benchmark studies lead to the design of model combos. We demonstrate that our combos can achieve new state-of-the-art performance on various datasets associated with cost-effective memory and computation.
Submission Length: Regular submission (no more than 12 pages of main content)
Changes Since Last Submission: We highlight our changes in both main content and appendix corresponding to different reviewers in color (blue, red and olive).
Assigned Action Editor: ~Gang_Niu1
Submission Number: 4012
Loading

OpenReview is a long-term project to advance science through improved peer review with legal nonprofit status. We gratefully acknowledge the support of the OpenReview Sponsors. © 2025 OpenReview